The popularity of Sildenafil initially fueled a surge for pharma, however recent shifts present a complicated outlook for investors. Generic versions are eating into revenue, and ongoing litigation add more difficulty https://junaidonrh868668.bluxeblog.com/73590837/the-blue-pill-and-big-pharma-a-precarious-bet